Abstract
Secukinumab is not superior to adalimumab for the treatment of active psoriatic arthritis, according to a multicentre, double-blind, head-to-head trial (the EXCEED study) by Iain B McInnes and colleagues. 853 patients were randomly assigned (1:1) to receive 300 mg subcutaneous secukinumab (n=426) or 40 mg subcutaneous adalimumab (n=427). 67% of patients in the secukinumab group achieved at least a 20% improvement on the American College of Rheumatology response criteria at week 52 (ACR20; the primary outcome) versus 62% of patients in the adalimumab group (odds ratio [OR] 1·30 [95% CI 0·98–1·72]; p=0·0719). The safety profiles of both drugs were consistent with previous reports; seven (2%) patients in the secukinumab group and six (1%) in the adalimumab group had serious infections.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
